Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01337089
Registration number
NCT01337089
Ethics application status
Date submitted
12/04/2011
Date registered
18/04/2011
Date last updated
12/04/2023
Titles & IDs
Public title
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Query!
Scientific title
A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Query!
Secondary ID [1]
0
0
2009-016529-32
Query!
Secondary ID [2]
0
0
GWCA0999
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Pain
0
0
Query!
Advanced Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Any cancer
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Experimental: Non-comparative, open-label Nabiximols - Nabiximols was self-administered by participants as a 100 microliter (µL) oromucosal spray, in the morning and evening, up to a maximum of 10 sprays per day for 6 months. Nabiximols oromucosal spray contained delta-9-tetrahydrocannabinol (THC) (27 milligrams \[mg\]/milliliter \[mL\]):cannabidiol (CBD) (25 mg/mL), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Each 100 µL actuation delivered 2.7 mg THC and 2.5 mg CBD.
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percent Of Participants With Treatment-emergent Adverse Events
Query!
Assessment method [1]
0
0
Treatment-emergent Adverse Events (TEAEs) were coded according to the Medical Dictionary for Regulatory Activities (MedDRA) dictionary version 17.0. A TEAE is defined as an adverse event with an onset after the start of study drug treatment. The percent of participants who experienced one or more TEAEs is reported.
Query!
Timepoint [1]
0
0
Baseline, Day 183
Query!
Secondary outcome [1]
0
0
Change From Baseline In Mean NRS Average Pain During The Last Period
Query!
Assessment method [1]
0
0
Participants indicated the level of pain experienced in the last 24 hours on an 11-point Numerical Rating Scale (NRS), where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine." Change in mean NRS average pain was calculated as: Last Period NRS average pain score - Baseline NRS average pain score.
A negative value indicates an improvement in average pain score from Baseline.
Query!
Timepoint [1]
0
0
Baseline, Last Period (Days 156-183) or last 27 days of treatment
Query!
Secondary outcome [2]
0
0
Change From Baseline In Mean Sleep Disruption NRS During The Last Period
Query!
Assessment method [2]
0
0
Participants indicated the level of sleep disruption experienced in the last 24 hours on an 11-point NRS, where a score of 0 indicated "did not disrupt sleep" and a score of 10 indicated "completely disrupted (unable to sleep at all)." Change in mean sleep disruption NRS was calculated as: Last Period sleep disruption NRS score - Baseline sleep disruption NRS score.
A negative value indicates an improvement in sleep disruption score from Baseline.
Query!
Timepoint [2]
0
0
Baseline, Last Period (Days 156-183) or last 27 days of treatment
Query!
Secondary outcome [3]
0
0
Patient Satisfaction Questionnaire At Last Visit (Up To Day 183)
Query!
Assessment method [3]
0
0
The Patient Satisfaction Questionnaire (PSQ) was used to assess level of satisfaction of the participant with the study drug, with the markers "extremely satisfied, very satisfied, slightly satisfied, neutral, slightly dissatisfied, very dissatisfied, extremely dissatisfied". Last visit refers to the last visit that a participant completed the assessment.
Query!
Timepoint [3]
0
0
Last Visit (up to Day 183)
Query!
Secondary outcome [4]
0
0
Change From Baseline In NRS Constipation At Last Visit (Up To Day 183)
Query!
Assessment method [4]
0
0
Participants indicated level of constipation on an 11-point NRS, where a score of 0 was "no constipation", and 10 was "constipation as bad as you can imagine." Last visit refers to the last visit that a participant completed the assessment.
Change in NRS constipation score was calculated as: Last Visit NRS constipation score - Baseline NRS constipation score.
A negative value indicates improvement in condition from Baseline.
Query!
Timepoint [4]
0
0
Baseline, Last Visit (up to Day 183)
Query!
Eligibility
Key inclusion criteria
* Participant had completed the parent study within the last seven days
* Willing and able to give written informed consent
* Willing and able to comply with all study requirements
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* The participant was using cannabis or cannabinoid based medications, other than the parent study investigational medicinal product (IMP), and was unwilling to abstain for the duration of the study
* Any history or immediate family history of schizophrenia, other psychotic illness, severe personality disorder or other significant psychiatric disorder other than depression associated with their underlying condition
* Any known or suspected history of a substance abuse/dependence disorder (including opiate abuse/dependence prior to the diagnosis of cancer), current heavy alcohol consumption (more than 60 grams [g] of pure alcohol per day for men, and more than 40 g of pure alcohol per day for women), current use of an illicit drug or current non-prescribed use of any prescription drug
* Had poorly controlled epilepsy or recurrent seizures (for example, one or more seizure during the last year)
* Had experienced myocardial infarction or clinically significant cardiac dysfunction within the last 12 months or had a cardiac disorder that, in the opinion of the investigator would have put the participant at risk of a clinically significant arrhythmia or myocardial infarction
* Had significantly impaired renal function
* Had significantly impaired hepatic function at the "end of treatment" visit of the parent study
* Female participants of child-bearing potential and male participants whose partner was of child-bearing potential, unless willing to ensure that they or their partner used effective contraception, for example, oral contraception, double barrier, intra-uterine device, during the study and for 3 months thereafter (however, a male condom should not have been used in conjunction with a female condom as this may not have proven effective)
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
NA
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
19/01/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
27/01/2016
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
660
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Parkville
Query!
Recruitment postcode(s) [1]
0
0
3050 - Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Kentucky
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Louisiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Minnesota
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Missouri
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Montana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New Jersey
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New York
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
North Carolina
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Ohio
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Pennsylvania
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Texas
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Utah
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Washington
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Bruxelles
Query!
Country [20]
0
0
Bulgaria
Query!
State/province [20]
0
0
Gabrovo
Query!
Country [21]
0
0
Bulgaria
Query!
State/province [21]
0
0
Varna
Query!
Country [22]
0
0
Bulgaria
Query!
State/province [22]
0
0
Vratsa
Query!
Country [23]
0
0
Czechia
Query!
State/province [23]
0
0
Benešov
Query!
Country [24]
0
0
Czechia
Query!
State/province [24]
0
0
Jablonec Nad Nisou
Query!
Country [25]
0
0
Czechia
Query!
State/province [25]
0
0
Most
Query!
Country [26]
0
0
Czechia
Query!
State/province [26]
0
0
Nová Ves Pod Pleší
Query!
Country [27]
0
0
Czechia
Query!
State/province [27]
0
0
Ostrava
Query!
Country [28]
0
0
Czechia
Query!
State/province [28]
0
0
Plzen
Query!
Country [29]
0
0
Czechia
Query!
State/province [29]
0
0
Sokolov
Query!
Country [30]
0
0
Czechia
Query!
State/province [30]
0
0
Teplice
Query!
Country [31]
0
0
Czechia
Query!
State/province [31]
0
0
Ceské Budejovice
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Berlin
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Frankfurt
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Jena
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Lunen
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Stadtroda
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Wetzlar
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Wiesbaden
Query!
Country [39]
0
0
Hungary
Query!
State/province [39]
0
0
Deszk
Query!
Country [40]
0
0
Hungary
Query!
State/province [40]
0
0
Komarom
Query!
Country [41]
0
0
Hungary
Query!
State/province [41]
0
0
Miskolc
Query!
Country [42]
0
0
Hungary
Query!
State/province [42]
0
0
Nyíregyháza
Query!
Country [43]
0
0
Hungary
Query!
State/province [43]
0
0
Szekszard
Query!
Country [44]
0
0
Hungary
Query!
State/province [44]
0
0
Szikszo
Query!
Country [45]
0
0
Israel
Query!
State/province [45]
0
0
Beer Sheva
Query!
Country [46]
0
0
Israel
Query!
State/province [46]
0
0
Haifa
Query!
Country [47]
0
0
Israel
Query!
State/province [47]
0
0
Ramat Gan
Query!
Country [48]
0
0
Israel
Query!
State/province [48]
0
0
Zerifin
Query!
Country [49]
0
0
Italy
Query!
State/province [49]
0
0
Garbagnate Milanese
Query!
Country [50]
0
0
Italy
Query!
State/province [50]
0
0
Piacenza
Query!
Country [51]
0
0
Italy
Query!
State/province [51]
0
0
Torino
Query!
Country [52]
0
0
Latvia
Query!
State/province [52]
0
0
Riga
Query!
Country [53]
0
0
Latvia
Query!
State/province [53]
0
0
Rezekne
Query!
Country [54]
0
0
Lithuania
Query!
State/province [54]
0
0
Klaipeda
Query!
Country [55]
0
0
Lithuania
Query!
State/province [55]
0
0
Siauliai
Query!
Country [56]
0
0
Lithuania
Query!
State/province [56]
0
0
Vilnius
Query!
Country [57]
0
0
Mexico
Query!
State/province [57]
0
0
Chihuahua
Query!
Country [58]
0
0
Mexico
Query!
State/province [58]
0
0
Distrito Federal
Query!
Country [59]
0
0
Poland
Query!
State/province [59]
0
0
Bialystok
Query!
Country [60]
0
0
Poland
Query!
State/province [60]
0
0
Bielsko-Biala
Query!
Country [61]
0
0
Poland
Query!
State/province [61]
0
0
Bydgoszcz
Query!
Country [62]
0
0
Poland
Query!
State/province [62]
0
0
Czeladz
Query!
Country [63]
0
0
Poland
Query!
State/province [63]
0
0
Czestochowa
Query!
Country [64]
0
0
Poland
Query!
State/province [64]
0
0
Dzialdowo
Query!
Country [65]
0
0
Poland
Query!
State/province [65]
0
0
Gdansk
Query!
Country [66]
0
0
Poland
Query!
State/province [66]
0
0
Gliwice
Query!
Country [67]
0
0
Poland
Query!
State/province [67]
0
0
Klodzko
Query!
Country [68]
0
0
Poland
Query!
State/province [68]
0
0
Opole
Query!
Country [69]
0
0
Poland
Query!
State/province [69]
0
0
Ostrowiec Swietokrzyski
Query!
Country [70]
0
0
Poland
Query!
State/province [70]
0
0
Poznan
Query!
Country [71]
0
0
Poland
Query!
State/province [71]
0
0
Warszawa
Query!
Country [72]
0
0
Poland
Query!
State/province [72]
0
0
Wloclawek
Query!
Country [73]
0
0
Puerto Rico
Query!
State/province [73]
0
0
Ponce
Query!
Country [74]
0
0
Puerto Rico
Query!
State/province [74]
0
0
San Juan
Query!
Country [75]
0
0
Romania
Query!
State/province [75]
0
0
Baia Mare
Query!
Country [76]
0
0
Romania
Query!
State/province [76]
0
0
Braila
Query!
Country [77]
0
0
Romania
Query!
State/province [77]
0
0
Bucuresti
Query!
Country [78]
0
0
Romania
Query!
State/province [78]
0
0
Cluj-Napoca
Query!
Country [79]
0
0
Romania
Query!
State/province [79]
0
0
Constanta
Query!
Country [80]
0
0
Romania
Query!
State/province [80]
0
0
Craiova
Query!
Country [81]
0
0
Romania
Query!
State/province [81]
0
0
Focsani
Query!
Country [82]
0
0
Romania
Query!
State/province [82]
0
0
Iasi
Query!
Country [83]
0
0
Romania
Query!
State/province [83]
0
0
Oradea
Query!
Country [84]
0
0
Romania
Query!
State/province [84]
0
0
Satu Mare
Query!
Country [85]
0
0
Romania
Query!
State/province [85]
0
0
Sibiu
Query!
Country [86]
0
0
Romania
Query!
State/province [86]
0
0
Suceava
Query!
Country [87]
0
0
Romania
Query!
State/province [87]
0
0
Târgoviste
Query!
Country [88]
0
0
Spain
Query!
State/province [88]
0
0
Granada
Query!
Country [89]
0
0
Taiwan
Query!
State/province [89]
0
0
Taichung
Query!
Country [90]
0
0
Taiwan
Query!
State/province [90]
0
0
Tainan City
Query!
Country [91]
0
0
United Kingdom
Query!
State/province [91]
0
0
Bury Saint Edmunds
Query!
Country [92]
0
0
United Kingdom
Query!
State/province [92]
0
0
Bury
Query!
Country [93]
0
0
United Kingdom
Query!
State/province [93]
0
0
Cheltenham
Query!
Country [94]
0
0
United Kingdom
Query!
State/province [94]
0
0
Crumpsall
Query!
Country [95]
0
0
United Kingdom
Query!
State/province [95]
0
0
Edinburgh
Query!
Country [96]
0
0
United Kingdom
Query!
State/province [96]
0
0
Gorleston-on-Sea
Query!
Country [97]
0
0
United Kingdom
Query!
State/province [97]
0
0
Leeds
Query!
Country [98]
0
0
United Kingdom
Query!
State/province [98]
0
0
Manchester
Query!
Country [99]
0
0
United Kingdom
Query!
State/province [99]
0
0
Norwich
Query!
Country [100]
0
0
United Kingdom
Query!
State/province [100]
0
0
Plymouth
Query!
Country [101]
0
0
United Kingdom
Query!
State/province [101]
0
0
Weston-super-Mare
Query!
Country [102]
0
0
United Kingdom
Query!
State/province [102]
0
0
Withington
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Jazz Pharmaceuticals
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
Otsuka Pharmaceutical Development & Commercialization, Inc.
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This was a six-month open-label extension (OLE) study to evaluate the safety of long-term nabiximols (Sativex®) therapy when used as an adjunctive treatment in participants with advanced cancer. The study provided continued availability of nabiximols to participants who completed a preceding Phase 3 study and new (de novo) participants.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01337089
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01337089
Download to PDF